Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of neuromuscular disability and ...

Ernesto Olvera, a Visalia resident, has been fighting a rare autoimmune disease known as chronic inflammatory demyelinating ...

Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t ...

HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased ...